Quick Search
DRUGCOAT L 30Ds dispersion form makes the product easier to process, reduces the need for organic solvents, and ensures better safety and environmental compatibility during pharmaceutical production.
DRUGCOAT L 30D creates smooth, uniform coatings with predictable dissolution behavior, making it suitable for a wide range of enteric dosage forms.
DRUGCOAT L 30D is generally considered low-hazard, although its polymer dispersion may cause mild skin or eye irritation upon direct contact.
CAS Number: 25212-88-8
Molecular Formula: C9H14O4
Molecular Weight: 186.21
Synonyms: 2-Propenoic acid, 2-methyl-, polymer with ethyl 2-propenoate, Ethylacrylat-Methacrylsure-Copolymer, 2-Propenoic acid, 2-methyl-, polymer with ethyl 2-propenoate Ethyl acrylate, methacrylic acid copolymer, methacrylic acid/ ethyl acrylate copolymer, Ethyl acrylate·methacrylic acid copolymer, Partially-Neutralized Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) (1 g), Kollicoat? MAE 30 DP, Methacrylic acid copolymer dispersion, 2-Propenoic acid, 2-methyl-, polymer with ethyl 2-propenoate, 607-646-8, RefChem:481741, 25212-88-8
DRUGCOAT L 30D polymer range of products has excellent potential as versatile & unique in different applications in NDDS including customized and newer applications.
Therefore, the pharma industry has now started looking for newer coating materials and is in a process of shifting from conventional coating materials to NEXTGEN polymer i.e. Methacrylic acid copolymers.
DRUGCOAT L 30D is an aqueous dispersion of methacrylic acid–ethyl acrylate copolymer designed specifically for use as an enteric coating material in pharmaceutical tablet and capsule formulations.
DRUGCOAT L 30D forms a protective polymer film around the dosage form that remains stable in the stomach but dissolves when it reaches higher pH levels in the small intestine.
This enables the controlled release of active pharmaceutical ingredients by preventing premature drug dissolution under acidic gastric conditions.
The polymer system in DRUGCOAT L 30D provides excellent film-forming properties that allow the coating to resist mechanical stress during manufacturing processes such as compression, drying, and packaging.
Inhalation of aerosolized particles or droplets during spraying operations may irritate the respiratory tract, especially in poorly ventilated areas.
Workers are therefore advised to use appropriate protective equipment such as gloves, goggles, and masks during handling and processing.
DRUGCOAT L 30D must be stored under controlled temperature conditions to prevent coagulation or instability of the polymer dispersion.
Spills should be cleaned with water before drying occurs, as dried residues can be difficult to remove and may cause slipping hazards.
Although it is not classified as a dangerous substance, good industrial hygiene practices should be followed to avoid unnecessary exposure and maintain product integrity.
DRUGCOAT L 30D provides excellent adhesion to tablet cores, allowing the coating to withstand abrasion, packaging movements, and transportation stresses without cracking or peeling.
Its formulation enables uniform film formation even at relatively low processing temperatures, which helps protect heat-sensitive pharmaceutical ingredients.
This combination of durability and gentle processing conditions makes it suitable for a wide variety of oral solid dosage forms.
The dispersion contains finely milled polymer particles that coalesce into a continuous protective layer when the coating is dried under controlled conditions.
This process creates a smooth and glossy surface that improves the aesthetic quality of tablets and can also enhance patient acceptance.
The resulting film shows stable behavior during storage, maintaining its integrity and dissolution properties over extended shelf-life periods.
Manufacturers often combine DRUGCOAT L 30D with plasticizers to improve flexibility and reduce brittleness of the final enteric film.
They may also incorporate colorants or pigments to differentiate products visually and to protect sensitive compounds from light exposure.
These formulation adjustments provide additional versatility and allow precise customization of coating performance based on the drug’s requirements.
DRUGCOAT L 30D maintains stable viscosity over long storage periods, which helps processors achieve predictable spray patterns during coating operations.
The controlled viscosity also reduces nozzle clogging, enabling smoother and more efficient production runs.
This reliability makes the material preferred for continuous large-scale manufacturing where workflow interruptions must be minimized.
When the dispersion is applied to tablets, its polymer droplets gradually merge as water evaporates, forming a uniform and defect-free enteric layer.
This coalescence behavior is sensitive to drying conditions, so manufacturers carefully control temperature and humidity to achieve optimal film properties.
The resulting film exhibits strong resistance to gastric fluid penetration, ensuring that the drug remains protected in low-pH environments.
The enteric film produced by DRUGCOAT L 30D shows good mechanical flexibility, which helps prevent cracking during handling, packaging, and transportation.
This flexibility is particularly important for tablets that undergo repeated motion such as during bottle filling or blister packing.
Maintaining the integrity of the coating ensures consistent drug release for every unit in a batch.
Density: 1.062-1.072
solubility: Practically insoluble in water (type A) or dispersible in water (type B), freely soluble in anhydrous ethanol, practically insoluble in ethyl acetate. It is freely soluble in a 40 g/L solution of sodium hydroxide.
PH: 2.1-3.0
Viscosity: ≤100mPa.s(23°C) (RV2100 PRMtype B)
LogP: 1.325 (est)
DRUGCOAT L 30D polymer range of products has excellent potential as versatile & unique in different applications in NDDS including customized and newer applications.
Therefore, the pharma industry has now started looking for newer coating materials and is in a process of shifting from conventional coating materials to NEXTGEN polymer i.e. Methacrylic acid copolymers.
Coating in oral solid dosage form is now very commonly used in pharmaceutical industry.
However, coating as such has its beginning with bitter taste masking of medicines in good old days with the help, of sugar coating.
This was very popular in Nutraceuticals & Herbal medicines.
Later on film coating concept came first time in early 1950’s courtesy Dr. Wurster under who’s name air suspension coating was patented.
Over the years, there have been several improvements in both the coating technologies as well as the coating material, which has brought the concept of functional coating as an important field in the pharmaceutical industry.
Ultimately, convenience, efficacy, safe drug delivery and economy of entire coating system are the four major criteria that were the Quiding factors in evolving ideal drug delivery system or a Novel Drug Delivery System i.e. NDDS.
This is possible only with the help of suitable choice of Acrylate polymers.
Thus it is obvious that our DRUGCOAT polymer range of products have excellent potential as versatile & unique in different application in NDDS including customized and newer application.
Therefore, pharma industry has now started looking for newer coating materials and is in a process of shifting from conventional coating materials to NEXTGEN polymeri.e. Methacrylic acid copolymers
Most of these coating polymers were developed through constant research & development work in company’s R&D centre and today company claims it’s products to be of world class quality conforming to highest standard technical specifications as prescribed in various monographs.
Company has a state-of-the-art manufacturing facility certified with International EXCiIPACT GMP certificate. ‘
VTIL’ today is proud of it’s full range of products and claimed to be the largest producer in this class of pharma polymers in India.
DRUGCOAT L 30D has acquired a clear leadership position in the industry.
DRUGCOAT L 30D is primarily used to produce enteric-coated tablets and capsules that must bypass the stomach and release their active ingredients in the intestine.
This makes it highly suitable for acid-sensitive drugs, drugs that irritate the gastric lining, or formulations requiring delayed-release profiles for therapeutic reasons.
Many pharmaceutical manufacturers use it to improve patient safety and drug efficacy by achieving targeted drug delivery and reducing side effects related to gastric exposure.
The product is also used in combination with plasticizers, anti-tacking agents, and pigments to optimize coating flexibility, appearance, and performance.
Its compatibility with standard coating equipment makes it a preferred industrial choice for large-scale production of oral solid dosage forms.
Formulators often choose DRUGCOAT L 30D because it offers consistent pH-dependent solubility, enabling reproducible dissolution profiles in regulatory testing and quality control environments.
Because DRUGCOAT L 30D is based on a pH-triggered polymer system, it resists dissolution in the stomach while completely dissolving in the upper intestine.
This predictable behavior protects drugs that are degraded by gastric acid, ensuring they reach their absorption site intact.
It also reduces gastric irritation for drugs that might otherwise cause discomfort or damage to the stomach lining.
Production processes using DRUGCOAT L 30D typically require standard coating equipment, making it easily adoptable in many pharmaceutical manufacturing lines.
Its water-based nature eliminates the need for flammable organic solvents, improving workplace safety and reducing environmental impact.
This also minimizes regulatory difficulties associated with solvent emissions, which is an important factor for modern pharmaceutical compliance.
Uses Of DRUGCOAT L 30D:
DRUGCOAT L 30D is widely used to produce enteric-coated tablets and capsules that must resist stomach acid and release their contents only in the small intestine.
This makes it an essential coating system for drugs that degrade in low-pH environments or require delayed absorption for therapeutic reasons.
By preventing premature dissolution in the stomach, it allows the drug to reach its target location intact and in optimal condition.
The material is frequently used for coating acid-sensitive medications such as certain enzymes, probiotics, and active ingredients that must avoid gastric degradation.
It also protects drugs that can irritate the stomach lining, reducing patient discomfort and improving treatment safety.
This approach enhances patient adherence by decreasing side effects associated with gastric exposure.
DRUGCOAT L 30D is used to create targeted-release formulations where the drug must dissolve at a specific pH level in the intestine for controlled therapeutic timing.
This helps maintain consistent drug levels in the bloodstream and can reduce dosing frequency for chronic medications.
Such controlled release performance contributes to improved pharmacokinetics and more stable therapeutic outcomes.
The material is applied in hot-melt or aqueous coating processes to create smooth and uniform films that enhance the mechanical strength of tablets.
These films help tablets withstand friction, compression forces, and packaging movements during transportation and storage.
The improved robustness ensures that the enteric function remains effective throughout the product’s shelf life.
Manufacturers also use DRUGCOAT L 30D in combination with pigments and plasticizers to develop visually appealing and flexible coatings tailored to specific drug formulations.
This customization helps differentiate products, improves patient recognition, and supports branding efforts in pharmaceutical markets.
At the same time, plasticizer-enhanced flexibility helps prevent film cracking on tablets with complex shapes or high mechanical stress.
Because DRUGCOAT L 30D is water-based, it is used to reduce or eliminate organic solvent usage during coating operations to improve environmental and workplace safety.
This supports sustainable pharmaceutical manufacturing practices while still maintaining high-quality enteric coating performance.
The shift away from solvent-based systems also decreases regulatory concerns related to emissions and solvent residues in final products.
DRUGCOAT L 30D is used in formulations that require the protection of moisture-sensitive drugs by providing an additional barrier that helps reduce water penetration.
This protective film can enhance the stability of compounds that degrade quickly in humid conditions, thereby extending their shelf life.
Such stabilization is especially beneficial for biopharmaceutical actives and advanced oral dosage technologies.
It is also used in combination therapies where multiple active ingredients must be released at different points in the gastrointestinal tract.
The coating helps separate incompatible ingredients by controlling when each drug is exposed to digestive fluids.
This enables the creation of complex multi-layer or multi-particulate systems that improve overall therapeutic efficiency.
Pharmaceutical companies use DRUGCOAT L 30D to improve the taste-masking properties of drug products by preventing early release of bitter compounds.
The enteric film reduces the patient’s exposure to unpleasant flavors during swallowing, which is particularly important for pediatric and geriatric dosage forms.
This creates a more pleasant administration experience and encourages better patient compliance.
The material is employed in large-scale continuous manufacturing processes due to its compatibility with modern spray-coating technologies.
Its consistent behavior during atomization and drying ensures reproducible coating thickness across thousands of tablets per batch.
This reliability makes it a preferred choice for industries that prioritize high throughput and minimal production variability.
DRUGCOAT L 30D is also used for pellet and granule coating in multiparticulate systems designed for adjustable dosing and modified-release characteristics.
These coated particles can be filled into capsules or compressed into tablets to create flexible dosing regimens.
This modular design helps clinicians tailor treatment strategies to individual patient needs.
The polymer dispersion is often used in research and development laboratories to prototype new oral drug delivery systems with pH-dependent release.
Researchers value its predictable dissolution profile, which makes it easier to study drug release kinetics under simulated gastrointestinal conditions.
Such controlled behavior allows precise optimization of formulations before scaling to industrial production.
DRUGCOAT L 30D is additionally used in formulations requiring superior adhesion to various core materials, including sugar spheres, microcrystalline cellulose pellets, or coated granules.
This strong adhesion ensures each particle remains uniformly coated without flaking or separation during processing.
The improved coating integrity contributes to consistent pharmacokinetic performance in multiparticulate dosage forms.
Safety Profile Of DRUGCOAT L 30D:
DRUGCOAT L 30D is generally considered a low-hazard material, but its liquid dispersion can cause mild skin irritation if it comes into prolonged contact with unprotected skin.
Workers may experience slight redness or dryness, especially if the product dries on the skin and forms a film.
For this reason, routine protective gloves are recommended during handling and transfer operations.
The dispersion may cause eye irritation if splashes enter the eyes, particularly because the polymer particles and stabilizers can disrupt the tear film.
This irritation typically presents as temporary redness, stinging, or blurred vision until the material is washed out.
Wearing protective goggles during spraying or mixing operations is therefore advised to prevent accidental exposure.
Inhalation of fine droplets or aerosols generated during spray-coating processes may irritate the respiratory tract.
Workers may experience coughing or a dry throat, especially in poorly ventilated coating rooms.
Adequate ventilation and appropriate respiratory protection help minimize this risk in industrial environments.
If the material dries on surfaces, the resulting film can create slip hazards in production areas.
These dried residues may become difficult to remove and can pose safety issues around equipment and walkways.
Regular cleaning procedures using water help maintain safe working conditions.
